Keywords: Tumors (Pre-Treatment), biomarkers, 2-hydroxyglutarate, IDH mutation, Glioma
Motivation: Detection of D-2-hydroxyglutarate (2-HG) using in-vivo magnetic resonance spectroscopy (MRS) is a highly promising potential biomarker for diagnosis and treatment monitoring in IDH-mutated glioma.
Goal(s): This study investigates how 2-HG estimates from unedited MRS (at optimized TE) depend on different modeling strategies.
Approach: We analyzed MRS data from patients with IDH-mutated glioma with different modeling strategies, focusing on the effect of spectral overlap on 2-HG quantification.
Results: Spectral overlap with metabolites like GABA and acetone can lead to false-positive 2-HG detections in normal-appearing contralateral brain tissue. Clinicians need to be mindful of these pitfalls when interpreting 2-HG estimates.
Impact: This study highlights that false-positive 2-HG MRS detection can occur in normal-appearing brain tissue and identifies signal overlap (with GABA, acetone, etc.) as the primary reason. 2-HG estimates should be interpreted carefully in clinical context, including dietary preferences or interventions.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords